In recent trading action Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock moved 1.11% landing at $152.42. This stock has garnered attention of analysts and investors over the past few weeks as the stock has come into mainstream focus.
Here we’ll take a quick glance at how the stock price is currently trading in relation to some of its simple moving averages. At current levels, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares have been seen trading -2.85% away from the 20-day moving average. The stock has been recently separated from the 50-day moving average by 5.25%. Using a broader approach, shares have been trading 15.92% off of the 200-day moving average. After the latest check-in, company stock is -10.50% off of the 50 day high and 20.49% away from the 50 day low price.
Analysts are predicting earnings per share growth of -101.00% for the current year. The earnings per share growth over the next five years are expected to be 27.50%. Ligand Pharmaceuticals Incorporated has had earnings per share growth of -17.40% over the past five years.
Earnings per share (EPS) the amount of income that “belongs” to each share of common stock. This is a valuable tool that investors use to determine the value and projected value of a stock. Earnings per share is generally reported in annualized form from the most recent fiscal year. To determine the value, the average number of shares outstanding is usually calculated by averaging the number of shares at the beginning of the fiscal period and the number of shares at the end of the period.
Currently the return on equity is 4.40% and its debt to equity is 0.60. Ligand Pharmaceuticals Incorporated has a total market cap of $3216.06, a gross margin of 94.90% while the profit margin is 12.80% and the ROI is 5.70%.
In terms of performance, we can pore into the stats for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). The stock is 11.31% since the start of 2017. Over the past week, shares are -0.18%. Moving out to look at the previous month performance, the stock is at 3.02%. For the quarter, performance is at 5.22%. During the past six months, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s stock has been 21.82% and 42.53% for the last 12 months.